# Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome

> **NCT00635674** · NA · COMPLETED · sponsor: **Pavol Jozef Safarik University** · enrollment: 32 (actual)

## Conditions studied

- Obstructive Sleep Apnea
- Metabolic Syndrome

## Interventions

- **DEVICE:** CPAP device - REMstar Plus, Respironics, Murrysville, USA

## Key facts

- **NCT ID:** NCT00635674
- **Lead sponsor:** Pavol Jozef Safarik University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2008-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635674, "Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00635674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*